Drugs for COVID-19 are sorted into three basic categories: They work, they don't work, or there simply isn't enough information to know. A generic steroid is one medicine that proved helpful.
A newly approved drug can extend the lives of children with progeria, a rare disorder that causes rapid aging. The drug is the result of one family's effort to help a child with the fatal condition.
Amazon launches an online pharmacy, sending shares of CVS, Walgreens and Rite Aid tumbling. Amazon has pushed to compete with Walmart and major pharmacy chains that have long offered home delivery.
Eli Lilly's monoclonal antibody will be available to people 65 or older or those with underlying health conditions. Supplies will be short, and allocating the medicine will be a challenge.
To boost the supply of Regeneron's antibody therapy for COVID-19, the federal government entered into a $450 million supply contract. Details of the deal show some safeguards are missing.
Experimental medicines have the potential to help people with COVID-19 avoid hospitalization. The scarce supply of the treatments would have to be rationed, if regulators OK their use.
Drugs are being tested that could reduce symptoms and save lives. But, given the way drugs are developed, it's unlikely that any single medicine will be anywhere as potent as a successful vaccine.
Emergency use authorization makes it easier for doctors to use a drug in a manner not specifically approved by the Food and Drug Administration. The FDA granted these drugs this status in March.
Experts say the Communist Party sees more at stake than public health. One of the biggest concerns is the economy. China is also looking to defuse criticism over its early handling of the outbreak.
An uproar followed comments by Sanofi's CEO that if the company develops a vaccine, doses would likely go to Americans first. The board president later insisted, "Any vaccine will be a public good."
Gilead Sciences is donating its initial supply of the experimental treatment for COVID-19. The federal government is deciding where the scarce medicine goes, and there are questions about the choices.
Gilead Sciences has committed to donating the initial supply of the experimental antiviral drug. But executives said the company will need to make expanded production of the treatment sustainable.
On Friday, the Food and Drug Administration authorized emergency use of remdesivir for patients with severe cases of COVID-19. Drugmaker Gilead Sciences' lobbying hit a new high in the first quarter.
Experts say it could be dangerous to rely on overseas production of medicine in a crisis, but the U.S. largely does. Rebuilding domestic capacity would take years and substantial investments.
Chloroquine and hydroxycloroquine got the Food and Drug Administration's go-ahead to be put in the nation's strategic storehouses. But the drugs haven't been approved to treat coronavirus patients.
Gilead Science's remdesivir, an antiviral medicine being tested for treatment of COVID-19, would get a seven-year monopoly if approved by the Food and Drug Administration.
A new report finds insurers are becoming more selective about which medications they'll cover. Patients and doctors have to work harder to get treatments approved.
Two nearly identical drug implants have very different prices. The one for kids has a list price of $37,300. For adults, it's $4,400. A dad fought for his daughter to be able to get the cheaper drug.
With drug costs on the rise — and insurers refusing to cover some prescriptions — even patients with insurance can find themselves facing high out-of-pocket costs or going without.
Changes in the way the Food and Drug Administration reviews new medicines means that there are more cures and treatments on the market. But there's also less proof the drugs are safe and effective.
Nearly 1 in 4 Americans has trouble affording prescription drugs, according to a Kaiser Family Foundation poll. Over the past decade, high prices of several medicines have become flashpoints.
